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N6-Isopentenyladenosine (iPA) is a cytokinin identified in plants but also present 
in a free form or as a modified nucleoside bound to selenocysteine tRNA in human 
cells. It is an adenosine modified by an isopentenyl chain which derives from dimeth-
ylallil pyrophosphate (DMAPP), an intermediate of the mevalonate pathway. iPA is 
required for efficient translational decoding of selenoproteins, and can modulate a 
variety of biological processes including cell cycle progression, DNA synthesis and 
apoptosis (1). Recently, it has been shown that iPA can exhibit immunomodulatory 
and anti-inflammatory properties by activating NK cells and modulating cytokine 
production in a way depending on the concentration used (2). In order to further 
investigate the anti-inflammatory properties of iPA and its possible mechanisms of 
action, we analyzed its ability to inhibit TNFα-induced inflammation, either in nor-
mal human bronchial epithelial cells or in a model of exacerbated inflammation rep-
resented by bronchial cells derived from a Cystic Fibrosis (CF) patient bearing the 
ΔF508 mutation. Results showed that iPA inhibited IL-8 and RANTES release in both 
type of cells in a different manner. The analysis of the key enzymes of the STAT3 
and NF-κB signalling pathways showed that iPA decreased the phosphorylation of 
STAT3 enzyme and markedly increased the expression of the direct NF-κB inhibitor, 
IκBα. These results were corroborated analyzing directly the NF-κB activity in HEK 
293/T cells transfected with a NF-κB reporter plasmid. In these cells, iPA was also 
able to decrease IκBα levels. Of interest, we found that iPA also increased the expres-
sion of the antioxidant selenoprotein glutathione peroxidase only in CF cells. Alto-
gether these data suggest that iPA can negatively regulate inflammation with a gen-
eral mechanism of action involving the inhibition of NF-κB pathway but also propose 
that, in the presence of an altered inflammatory response such as in CF disease, iPA 
might act by modulating expression and/or synthesis of glutathione peroxidase.
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